The continuing liberalization of cannabis laws such as the hemp removal as a controlled substance in Texas, supports the work KALY is advancing.
DALLAS, March 26, 2019 (GLOBE NEWSWIRE) — via OTC PR WIRE
Kali-Extracts, Inc. (Kali, Inc. dba/Kali-Extracts, Inc.) (USOTC: KALY) (“KALY”) today announced that the State of Texas plans to remove hemp as a controlled substance next week in conjunction with the United States 2018 Farm Act, just the type of market condition management is looking for to support the implantation of the previously announced cannabis extraction lab to be dedicated to the 100 acre hemp farm to be operated by partner Nouveau (USOTC: NOUV) in Texas.
KALY and NOUV plan to partner on the development of a proprietary hemp cultivar dedicated to the advancement of KALY’s pharmaceutical extract developments.
The continuing liberalization of cannabis laws such as the hemp removal as a controlled substance in Texas, supports the work KALY is advancing.
Last week, KALY published a research report on the recent pilot treatment of Chronic Obstructive Pulmonary Disease (COPD) in primates using an extract derived from KALY’s patented cannabis extraction process.
- The report details the study method and the significance of the study.
- The report includes specific findings and due to the substantial findings, the report includes guidelines for next stage tests.
KALY is a health and wellness company set to generate revenue from its patented cannabis extraction technology through overlapping go-to-market strategies. In addition to developing pharmaceutical products internally and through partnerships, KALY is utilizing its patented cannabis extraction process to develop numerous wellness products both internally and through partnerships.
The first revenue generating contracts signed in December of 2018 will be reflected in the company’s upcoming annual report.
